FDA In Brief: FDA & European Medicines Agency collaborate on drug quality and manufacturing data to improve patient access to medically necessary medications

https://www.fda.gov/news-events/fda-brief/fda-brief-fda-european-medicines-agency-collaborate-drug-quality-and-manufacturing-data-improve?utm_campaign=07312019_FiB_FDA%20%26%20EMA%20collaborate%20on%20drug%20quality%20for%20Breakthrough%20Therapies&utm_medium=email&utm_source=Eloqua

FDA In Brief: FDA & European Medicines Agency collaborate on drug quality and manufacturing data to improve patient access to medically necessary medications

The FDA and the European Medicines Agency (EMA) are publishing the discussion and main conclusions from a workshop held on November 26, 2018, at the EMA headquarters in London, supporting quality development for the FDA’s Breakthrough Therapy Designation and EMA’s Priority Medicines (PRIME) programs for patients with unmet medical needs. The workshop between regulators and industry discussed quality challenges and scientific and regulatory approaches for facilitating development and preparation of robust quality data packages, to enable timely access to medicines for patients while keeping in mind the importance of drug safety and quality and maintaining current standards of approval.

Read More